FY2024 EPS Forecast for Aprea Therapeutics Lifted by Analyst

Aprea Therapeutics, Inc. (NASDAQ:APRE) – Research analysts at HC Wainwright lifted their FY2024 EPS estimates for Aprea Therapeutics in a research report issued to clients and investors on Monday, November 18th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings per share of ($2.39) for the year, up from their previous estimate of ($2.41). HC Wainwright has a “Buy” rating and a $20.00 price objective on the stock. The consensus estimate for Aprea Therapeutics’ current full-year earnings is ($2.56) per share. HC Wainwright also issued estimates for Aprea Therapeutics’ Q4 2024 earnings at ($0.54) EPS, FY2025 earnings at ($0.95) EPS, FY2026 earnings at ($0.86) EPS and FY2027 earnings at ($0.61) EPS.

Aprea Therapeutics (NASDAQ:APRE) last posted its earnings results on Thursday, November 7th. The company reported ($0.64) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.11. The firm had revenue of $0.35 million for the quarter, compared to analyst estimates of $0.45 million. Aprea Therapeutics had a negative return on equity of 57.86% and a negative net margin of 1,029.50%.

Separately, Wedbush reissued an “outperform” rating and set a $11.00 price objective on shares of Aprea Therapeutics in a research report on Tuesday, August 13th.

Aprea Therapeutics Stock Performance

Shares of APRE stock opened at $3.02 on Wednesday. Aprea Therapeutics has a 52 week low of $2.15 and a 52 week high of $8.85. The company’s 50 day moving average price is $3.33 and its two-hundred day moving average price is $3.86. The company has a market capitalization of $16.41 million, a P/E ratio of -1.07 and a beta of 0.97.

Insider Activity at Aprea Therapeutics

In other Aprea Therapeutics news, Director Bernd R. Seizinger acquired 10,000 shares of the stock in a transaction dated Friday, October 11th. The shares were bought at an average cost of $2.68 per share, for a total transaction of $26,800.00. Following the completion of the acquisition, the director now directly owns 44,730 shares of the company’s stock, valued at approximately $119,876.40. This trade represents a 28.79 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Marc Duey sold 6,462 shares of the business’s stock in a transaction on Friday, October 18th. The stock was sold at an average price of $4.58, for a total transaction of $29,595.96. Following the completion of the sale, the director now directly owns 233,651 shares in the company, valued at approximately $1,070,121.58. This represents a 2.69 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have bought 42,290 shares of company stock valued at $165,096. 12.80% of the stock is owned by insiders.

Institutional Investors Weigh In On Aprea Therapeutics

A hedge fund recently bought a new stake in Aprea Therapeutics stock. Stonepine Capital Management LLC bought a new stake in Aprea Therapeutics, Inc. (NASDAQ:APRE) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 137,174 shares of the company’s stock, valued at approximately $558,000. Aprea Therapeutics comprises 0.5% of Stonepine Capital Management LLC’s investment portfolio, making the stock its 21st largest position. Stonepine Capital Management LLC owned about 2.53% of Aprea Therapeutics as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 34.19% of the company’s stock.

Aprea Therapeutics Company Profile

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.